Found 26 Lancaster General Health trials
A listing of Lancaster General Health medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
The PK Papyrus Covered Coronary Stent System (PK Papyrus) received approval under a Humanitarian Device Exemption (HDE H170004) from the Food and Drug Administration on September 14, 2018 and is only indicated for treatment of acute perforations of native coronary arteries and coronary bypass grafts in vessels 2.5 to 5.0 …
The overall objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery.
The OPTIMIZER Smart Post-Approval Study (PAS) is a single arm open label study of 620 participants receiving an OPTIMIZER implant as standard of care. Patients to be included will have NYHA functional class III symptoms and a left ventricular ejection fraction of 25-45%.
This research study seeks to validate how echocardiogram (echo) data predicts response to cardiac resynchronization therapy (CRT) provided by a CRT device with a defibrillator (CRT-D) in individuals without the heart arrhythmia abnormality left bundle branch block (LBBB). It also aims to identify new variables recorded from electrocardiograms (ECG) or …
This study will determine if ziltivekimab, a monoclonal antibody, can be used to treat people living with heart failure and inflammation. Previous studies showed that ziltivekimab can lower inflammation, which may have a positive effect on heart failure symptoms. The HERMES study will look more into this effect. Also, the …
This post-approval study (PAS) evaluates real world usage of the ENROUTE Transcarotid Stent when used with the ENROUTE Transcarotid Neuroprotection System in patients at standard risk for adverse events from carotid endarterectomy (a procedure to treat carotid artery disease). The study will enroll up to 400 patients at 30-60 sites …
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absence of circulating tumor DNA (ctDNA) after surgery for colon cancer.This study is Enrolling by Invitation only at Lancaster General Health - ABBCI.
This study compares the impact of using a combination of drugs, ramucirumab and pembrolizumab, versus standard chemotherapy for treating advanced non-small cell lung cancer that is stage IV or recurrent. Ramucirumab blocks new blood vessel growth that tumors need, while pembrolizumab boosts the immune system to fight cancer. The trial …
This study will compare the good and bad effects of not giving regional radiotherapy versus using regional radiotherapy in patients with low risk breast cancer as indicated by Oncotype DX Recurrence Score. This is intended to help researchers discover if not giving regional radiotherapy will be as beneficial as using …
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer …
